why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
First received: July 15, 2025

Clinical Trial: Upadacitinib for Refractory Behcet's Syndrome

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Behcet Syndrome

Study Type: INTERVENTIONAL


Official Title: Upadacitinib for Refractory Behcet's Syndrome: a Prospective Pilot Open-label Study

Brief Summary: Behçet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system.Refractory BS poses significant treatment challenges, necessitating novel therapeutic approaches.Upadacitinib, a selective JAK1 inhibitor within the JAK-STAT pathway, has shown promise in modulating immune responses.This study aims to evaluate the efficacy and safety of upadacitinib in patients with refractory BS.

Read more